Literature DB >> 10221747

Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain.

G Liebsch1, R Landgraf, M Engelmann, P Lörscher, F Holsboer.   

Abstract

The purpose of this study was to investigate the functional role the two corticotropin-releasing hormone (CRH) receptor subtypes play in regulating the behavioural performance of rats in various well-defined test situations. Antisense oligodeoxynucleotides (ODNs) corresponding to either the rat CRH1 or CRH2 receptor mRNA were infused chronically into the lateral ventricle of male rats via osmotic minipumps (5 microg/0.5 microl/h over 6 days). Control groups received infusions of either a scrambled sequence ODN or mixed bases ODN or vehicle. On day 4 after surgery, the rats were subjected to 10 min of social defeat and immediately afterwards tested on the elevated plus-maze. Compared to a scrambled sequence control ODN, CRH1 receptor antisense ODN infusion was found to exert an anxiolytic-like effect whereas CRH2 receptor antisense ODN infusion had no effect on defeat-induced anxiety-related behaviour. In contrast, the CRH2 receptor antisense ODN increased immobility in a forced swim test whereas CRH1 receptor ODN-treated rats did not differ from controls. No influence of either ODN was found on general locomotor activity in an open field or on short-term memory performance in a social discrimination test. Furthermore, the CRH2 receptor antisense ODN did not affect spatial learning in a Morris water maze task. An additional experiment comparing a mixture of both missense ODNs and a vehicle control group confirmed that the former failed to induce non-specific (toxic) side effects, further substantiating the specificity of the respective antisense effects measured in this study. The results support the hypothesis that the two CRH receptor subtypes selectively mediate differential effects of endogenous CRH or CRH-related peptides at the brain level with the CRHI receptor contributing predominantly to emotional behaviour and the CRH2 receptor being involved in the regulation of stress coping behaviour.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221747     DOI: 10.1016/s0022-3956(98)80047-2

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  26 in total

1.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

2.  Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis.

Authors:  Kendall M Carlin; Wylie W Vale; Tracy L Bale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 3.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats.

Authors:  Cindy K Funk; Eric P Zorrilla; Mei-Jing Lee; Kenner C Rice; George F Koob
Journal:  Biol Psychiatry       Date:  2006-07-28       Impact factor: 13.382

Review 5.  Urocortins: CRF's siblings and their potential role in anxiety, depression and alcohol drinking behavior.

Authors:  Andrey E Ryabinin; Michael M Tsoory; Tamas Kozicz; Todd E Thiele; Adi Neufeld-Cohen; Alon Chen; Emily G Lowery-Gionta; William J Giardino; Simranjit Kaur
Journal:  Alcohol       Date:  2012-03-22       Impact factor: 2.405

6.  Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

Authors:  K H Skelton; C B Nemeroff; D L Knight; M J Owens
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 7.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 8.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.

Authors:  Victoria B Risbrough; Richard L Hauger; Mary Ann Pelleymounter; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.

Authors:  Aju Abraham; Stuart Watson; Allan H Young
Journal:  Indian J Psychiatry       Date:  2003-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.